New developments in immunotherapy drugs continue to create buzz in the cancer community and beyond. This special issue discusses key developments in immunotherapy, highlighting new advances and providing resources for patients, their family members, and their oncology navigators.
Several immune checkpoint inhibitors are now approved for patients with non-small-cell lung cancer, giving hope to patients living with this disease.
“CAR T-cell therapy provides an exciting and additional option for patients who have failed more traditional regimens,” says Dr. Gwen Nichols, Chief Medical Officer for Leukemia & Lymphoma Society.
By Wayne Kuznar
The National Comprehensive Cancer Care Network and the American Society of Clinical Oncology recently issued the first set of recommendations for the management of immunotherapy side-effects.
Patients who are receiving immunotherapy should consult with their doctor immediately if and when any side effects occur, because immune-related adverse events may occur during therapy or even after discontinuation of therapy.
Enter immunotherapy, stage left. This bright star has gained some traction over the past 2 decades, with the promise of more effective and less hazardous ways to combat cancer.
CAR T-cell therapy is a new type of immunotherapy that uses the patient’s genetically modified immune T-cells to attack cancer cells. In 2017, the FDA approved the first 2 CAR T-cell therapies for several types of blood cancer.
What Is Personalized Medicine, and Why Is It Important for Cancer Treatment? Interview with Dr. Ross Maclean
An interview with Ross Maclean, MD, PhD, Senior Vice President, Head of Medical at Precision Health Economics, Princeton, NJ, about the importance of personalized medicine in the treatment of cancer.
Cancer ResearchImmunotherapyLung Cancer
Significant developments in the treatment of lung cancer were reported at the 2017 annual meeting of the European Society for Medical Oncology (ESMO) in Madrid, Spain.
Page 1 of 3
Results 1 - 10 of 24
Results 1 - 10 of 24